Overview

Also Known As: motor neuron degeneration

These mice carry a spontaneous mutation at the Cln8 locus characterized by hindlimb weakness, ataxia, and early death.

Genetic overview

Genetic Background	Generation

Cln8^mnd

Allele Type	Gene Symbol	Gene Name
Spontaneous	Cln8	ceroid-lipofuscinosis, neuronal 8

View Genetics

Research Applications

Neurobiology Research
Sensorineural Research

View All Research Applications

Base Price

Starting at:

$2,854.50 Domestic price Cryo Recovery

View Price List

Details

Detailed Description

Mice homozygous for the motor neuron degeneration (mnd) spontaneous mutation show onset of disease between 5 and 11 months. Disease characterics include hindlimb weakness and ataxia which progresses to severe spastic paralysis of all limbs, with death usually by 9 to 14 months. Histological examination of the nervous system of affected animals shows sudanophyllic, autofluorescent intraneuronal inclusions characteristic of human neuronal ceroid lipofuscinosis suggesting that mnd mice are models for such human disease as Batten's disease. Performance at 14-16 weeks of age in an associative learning task is significantly decreased relative to controls, thus providing an early disease phenotype for this neuronal ceroid lipofuscinosis model. (Wendt KD, et al., 2005) Males and females are equally affected and both are fertile, although breeding efficiency is reduced.

Homozygous mnd mice exhibit a retinopathy characterized by an early and progressive degeneration which primarily involves loss of photoreceptor cells and subsequently affects retinal neuronal cells (Guarneri R et al., 2004).

Control Suggestions

000664 C57BL/6J

Additional Information

Considerations for Choosing Controls

Selected References

Messer A; Plummer J; Maskin P; Coffin JM; Frankel WN. 1992. Mapping of the motor neuron degeneration (Mnd) gene, a mouse model of amyotrophic lateral sclerosis (ALS). Genomics 13(3):797-802PubMed: 1639406 MGI: J:1224
Bronson RT; Lake BD; Cook S; Taylor S; Davisson MT. 1993. Motor neuron degeneration of mice is a model of neuronal ceroid lipofuscinosis (Batten's disease). Ann Neurol 33(4):381-5PubMed: 7683855 MGI: J:12816
Messer A; Flaherty L. 1986. Autosomal dominance in a late-onset motor neuron disease in the mouse. J Neurogenet 3(6):345-55PubMed: 3783318 MGI: J:8492

View All References

Genetics

Cln8^mnd

Allele Symbol: Cln8^mnd

Allele Name	motor neuron degeneration
Allele Type	Spontaneous
Allele Synonym(s)	motor neuron degeneration; Cln8^mnd
Gene Symbol and Name	Cln8, ceroid-lipofuscinosis, neuronal 8
Gene Synonym(s)	mnd; motor neuron degeneration; EPMR; C8orf61; TLCD6
Strain of Origin	B6.KB2-H2^b5
Chromosome	8
General Note	Early papers (J:8492, J:1224) state that this allele exhibits phenotypic similarity to amytrophic lateral sclerosis (ALS), however further analysis (J:12816, 56219) revealed that it is a better model for neuronal ceroid lipofuscinoses (Batten's disease) than for ALS.
Molecular Note	A single nucleotide insertion (267-268C, codon 90) predicts a frameshift and a truncated protein.

Disease/Phenotype

Disease Terms

Model with phenotypic similarity to human disease where etiologies involve orthologs. Human genes are associated with this disease. Orthologs of those genes appear in the mouse genotype(s).

neuronal ceroid lipofuscinosis 8

Research Areas By Genotype

This mouse can be used to support research in many areas including:

Genotype: Cln8^mnd related

Neurobiology Research
- Ataxia (Movement) Defects
- Behavioral and Learning Defects
- Metabolic Defects
- Neurodegeneration
- Neuromuscular defects
Sensorineural Research
- Retinal Degeneration

Mammalian Phenotype Terms by Genotype

The following phenotype information is associated with a similar, but not exact match to this JAX^® Mice strain

Genotype: Cln8^mnd/Cln8^mnd
involves: AKR/J * B6.KB2

mortality/aging

premature death
- Background Sensitivity - death by 7 months of age, compared to 9-14 months on the inbred B6.KB2 background

vision/eye phenotype

abnormal retinal photoreceptor layer morphology

abnormal retinal pigment epithelium morphology
- focal thinning of the retinal pigment epithelium occurs at late stages of degeneration

abnormal retinal rod cell inner segment morphology
- rapid thinning of the rod inner segment layer by P25, with a more gradual thinning at later stages

abnormal retinal rod cell outer segment morphology
- rapid thinning of the rod outer segment layer by P25, with a more gradual thinning at later stages

retinal degeneration
- detectable at P15 and more pronounced with age

short photoreceptor inner segment
- at very late stages of degeneration, inner segments are shortened and broadened

short photoreceptor outer segment
- progressive shortening of the outer segments while maintaining relatively normal structure

thin retinal outer nuclear layer
- at P15, the outer nuclear layer (ONL) contains greater number of pyknotic nuclei and is thinner
- rapid thinning of the ONL by P25, with a more gradual thinning at later ages

nervous system phenotype

abnormal motor neuron morphology
- Background Sensitivity - motor neuron disease is accelerated with 40% exhibiting symptoms by 4.5 months of age and dying by 6.5-7 months

abnormal nervous system morphology
- Background Sensitivity - earlier age of onset (4.5-5 months) and increased speed of progression of neurological disease than on the inbred B6.KB2 background

abnormal retinal rod cell inner segment morphology
- rapid thinning of the rod inner segment layer by P25, with a more gradual thinning at later stages

abnormal retinal rod cell outer segment morphology
- rapid thinning of the rod outer segment layer by P25, with a more gradual thinning at later stages

short photoreceptor inner segment
- at very late stages of degeneration, inner segments are shortened and broadened

short photoreceptor outer segment
- progressive shortening of the outer segments while maintaining relatively normal structure

pigmentation phenotype

abnormal retinal pigment epithelium morphology
- focal thinning of the retinal pigment epithelium occurs at late stages of degeneration

Genotype: Cln8^mnd/Cln8^mnd
involves: B6.KB2 * C3H/HeJ

mortality/aging

premature death
- Background Sensitivity - death similar to that seen on the inbred B6.KB2 background

nervous system phenotype

abnormal motor neuron morphology
- Background Sensitivity - exhibit motor neuron disease symptoms at around 6 months of age and do not die prior to 10-12 months of age

abnormal nervous system morphology
- Background Sensitivity - neurological disease progresses in a similar fashion as on the inbred B6.KB2 background

Genotype: Cln8^mnd/Cln8^mnd
AK.B6(Cg)-Cln8

mortality/aging

premature death
- Background Sensitivity - die by 5.5 months of age

nervous system phenotype

abnormal motor neuron morphology
- Background Sensitivity - motor neuron disease is accelerated even more than in the mixed AKR/J and B6.KB2 background, with symptoms appearing by 4 months and death by 5.5 months of age

The following phenotype relates to a compound genotype created using this strain

Genotype: Cln8^mnd/Cln8^mnd
B6.KB2/Rn-Cln8

behavior/neurological phenotype

abnormal locomotor behavior
- dragging or splaying of the hindlimbs while walking
- unable to walk uphill

abnormal motor capabilities/coordination/movement
- hindlimbs are unable to grasp the bars of wire cagetop when attempting to walk over it

ataxia
- age of onset is approximately 5- 11 months of age, progressive with age

hindlimb paralysis
- age of onset is approximately 5- 11 months of age, progressive with age

limb grasping

paralysis
- progress to severe spastic paresis and paralysis by 9 months of age

paresis
- begin to develop paresis by 6 months of age

nervous system phenotype

abnormal cranial nerve morphology
- degeneration of cranial nerves

abnormal hypoglossal nerve morphology
- degenerating

abnormal motor neuron morphology
- Background Sensitivity - exhibit motor neuron disease symptoms at around 6 months of age
- inclusion bodies containing ubiquitin were found in spinal neurons of mnd mice, even prior to onset of symptoms
- motor neurons have eccentric or indiscrete nuclei, disrupted membranes and shape changes

abnormal nervous system morphology
- contain LFB-positive intracytoplasmic inclusion material in most neurons in virtually all parts of the brain and spinal cord unlike in controls

abnormal spinal cord ventral horn morphology
- degeneration of anterior horn cells in the spinal cord

abnormal vagus nerve morphology
- degenerating dorsal motor vagus

motor neuron degeneration
- degeneration of the upper and lower motor neurons of the spinal cord and cranial nerves and of some areas of the brain

reproductive system phenotype

decreased litter size
- lower number of progeny/litter and lower numbers of total litters

vision/eye phenotype

abnormal retinal photoreceptor layer morphology
- atrophy of the photoreceptor layer in mice older than 3 months and nearly complete loss of this layer by 8 months of age

blindness
- begin to become blind by 2 months of age and by 5 months, are completely blind

mortality/aging

premature death
- Background Sensitivity - most die by 9-14 months of age

Genotype: Cln8^mnd/Cln8⁺
involves: B6.KB2 * C57BL/6Fla

nervous system phenotype

abnormal motor neuron morphology
- exhibit neurological disease, with onset of mild symptoms at an age (5 months) similar to homozygotes
- NOTE: It was originally thought that heterozygoous mice as old as 18 months could be visually identified; however, it has been impossible to repeat these results- no histological pathology is detectable.
- slower emergence of more severe motor neuron disease symptoms than in homozygotes

Genotype: Cln8^mnd/Cln8^mnd
involves: B6.KB2

behavior/neurological phenotype

seizures
- terminal seizures have been seen

nervous system phenotype

abnormal myelination
- lesions in the spinal cord are consistent with Wallerian degeneration
- many profiles of degenerating myelin sheaths and axons are seen in the white matter of the spinal cord

axon degeneration
- Normal - however, no necrotic or apoptotic nuclei are detected in the central nervous system
- lesions in the spinal cord are consistent with Wallerian degeneration
- many profiles of degenerating myelin sheaths and axons are seen in the white matter of the spinal cord

gliosis

seizures
- terminal seizures have been seen

References

Messer A; Plummer J; Maskin P; Coffin JM; Frankel WN. 1992. Mapping of the motor neuron degeneration (Mnd) gene, a mouse model of amyotrophic lateral sclerosis (ALS). Genomics 13(3):797-802PubMed: 1639406 MGI: J:1224
Bronson RT; Lake BD; Cook S; Taylor S; Davisson MT. 1993. Motor neuron degeneration of mice is a model of neuronal ceroid lipofuscinosis (Batten's disease). Ann Neurol 33(4):381-5PubMed: 7683855 MGI: J:12816
Messer A; Flaherty L. 1986. Autosomal dominance in a late-onset motor neuron disease in the mouse. J Neurogenet 3(6):345-55PubMed: 3783318 MGI: J:8492

Additional References

Messer A; Plummer J; Wong V; Lavail MM. 1993. Retinal degeneration in motor neuron degeneration (mnd) mutant mice [letter] Exp Eye Res 57(5):637-41PubMed: 8282051 MGI: J:19328
Messer A; Plummer J; MacMillen MC; Frankel WN. 1995. Genetics of primary and timing effects in the mnd mouse. Am J Med Genet 57(2):361-4PubMed: 7668363 MGI: J:25748
Mazurkiewicz JE. 1991. Ubiquitin deposits are present in spinal motor neurons in all stages of the disease in the motor neuron degeneration (Mnd) mutant of the mouse. Neurosci Lett 128(2):182-6PubMed: 1658691 MGI: J:624
Chang B; Hawes NL; Hurd RE; Davisson MT; Nusinowitz S; Heckenlively JR. 2002. Retinal degeneration mutants in the mouse. Vision Res 42(4):517-25PubMed: 11853768 MGI: J:75095
Guarneri R; Russo D; Cascio C; D'Agostino S; Galizzi G; Bigini P; Mennini T; Guarneri P. 2004. Retinal oxidation, apoptosis and age- and sex-differences in the mnd mutant mouse, a model of neuronal ceroid lipofuscinosis. Brain Res 1014(1-2):209-20PubMed: 15213005 MGI: J:90947

Additional - Cln8^mnd related

Technical Support

Contact Technical Support

Genotyping Protocols
- Standard PCR: Cln8^mnd
- Genotyping resources and troubleshooting
Appearance
- black, ataxic
  Related Genotype: a/a Cln8^mnd/Cln8^mnd
Citation
When using the motor neuron degeneration mouse strain in a publication, please cite the originating article(s) and include JAX stock #001612 in your Materials and Methods section.

Animal Health Reports

Facility Barrier Level Descriptions

Production of mice from cryopreserved embryos or sperm occurs in a maximum barrier room, G200

Pricing & Availability

Cryo Recovery

Domestic
International

Live Mouse

Age

Genotype

Price

weeks

Cryorecovery - Pricing

Service	Genotype	Price
	Homozygous for Cln8<mnd>, 1 pair minimum

We will fulfill your order by providing at least two carriers for each strain ordered. The total number, sex, and genotypes provided will vary, although typically 8 or more animals are provided. Please check genotypes which will be recovered. While the genotypes of all animals produced will be communicated to you prior to scheduling shipment, the genotypes of animals provided may not reflect the mating scheme and genotypes described in the strain description. Animals are typically ready to ship in 11-14 weeks. If a second recovery is required to produce the minimum number of animals, then delivery time would increase to approximately 25 weeks. If we fail to produce animals of the correct genotype, you will not be charged. We cannot guarantee the reproductive success of mice shipped to your facility. If the mice are lost after the first three days (post-arrival) or do not produce progeny at your facility, a new order and fee will be necessary.

Cryorecovery to establish a Dedicated Supply for greater quantities of mice. Mice recovered can be used to establish a dedicated colony to contractually supply you mice according to your requirements. Price by quotation.

Payment Terms and Conditions

Terms are granted by individual review and stated on the customer invoice(s) and account statement. These transactions are payable in U.S. currency within the granted terms. Payment for services, products, shipping containers, and shipping costs that are rendered are expected within the payment terms indicated on the invoice or stated by contract. Invoices and account balances in arrears of stated terms may result in The Jackson Laboratory pursuing collection activities including but not limited to outside agencies and court filings.

The Jackson Laboratory's Genotype Promise

The Jackson Laboratory has rigorous genetic quality control and mutant gene genotyping programs to ensure the genetic background of JAX® Mice strains as well as the genotypes of strains with identified molecular mutations. JAX® Mice strains are only made available to researchers after meeting our standards. However, the phenotype of each strain may not be fully characterized and/or captured in the strain data sheets. Therefore, we cannot guarantee a strain's phenotype will meet all expectations. To ensure that JAX® Mice will meet the needs of individual research projects or when requesting a strain that is new to your research, we suggest ordering and performing tests on a small number of mice to determine suitability for your particular project.

Terms Of Use

Terms of Use

General Terms and Conditions

Questions about Terms of Use

Licensing Information

Phone: 207-288-6470

Email: TechTran@jax.org

JAX® Mice, Products & Services Conditions of Use

"MICE" means mouse strains, their progeny derived by inbreeding or crossbreeding, unmodified derivatives from mouse strains or their progeny supplied by The Jackson Laboratory ("JACKSON"). "PRODUCT(S)" means biological materials supplied by JACKSON, and their derivatives. "SERVICES" means projects conducted by JACKSON for other parties that may include but are not limited to the use of MICE or PRODUCTS. "RECIPIENT" means each recipient of MICE, PRODUCTS, or SERVICES provided by JACKSON including each institution, its employees and other researchers under its control. MICE or PRODUCTS shall not be: (i) used for any purpose other than internal research, (ii) sold or otherwise provided to any third party for any use, or (iii) provided to any agent or other third party to provide breeding or other services. Acceptance of MICE, PRODUCTS or SERVICES from JACKSON shall be deemed as agreement by RECIPIENT to these conditions, and departure from these conditions requires JACKSON’s prior written authorization.

No Warranty

MICE, PRODUCTS AND SERVICES ARE PROVIDED "AS IS". JACKSON EXTENDS NO WARRANTIES OF ANY KIND, EITHER EXPRESS, IMPLIED, OR STATUTORY, WITH RESPECT TO MICE, PRODUCTS OR SERVICES, INCLUDING ANY IMPLIED WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, OR ANY WARRANTY OF NON-INFRINGEMENT OF ANY PATENT, TRADEMARK, OR OTHER INTELLECTUAL PROPERTY RIGHTS.

Credit for PRODUCTS or SERVICES

In case of dissatisfaction for a valid reason and claimed in writing by a purchaser within ninety (90) days of receipt of, PRODUCTS or SERVICES, JACKSON will, at its option, provide credit or replacement for the PRODUCT received or the SERVICES provided; JACKSON makes no other representations and this shall be the exclusive remedy of the purchaser. Please note specific policy for live mice.

Animal Care and Use for SERVICES

Consistent with the requirement for a written understanding regarding animal care and use, the JACKSON Animal Care and Use Committee will review the animal care and use protocol(s) associated with any SERVICES to be performed at JACKSON, and JACKSON shall have ultimate responsibility and authority for the care of animals while on site or in JACKSON custody.

No Liability

In no event shall JACKSON, its trustees, directors, officers, employees, and affiliates be liable for any causes of action or damages, including any direct, indirect, special, or consequential damages, arising out of the provision of MICE, PRODUCTS, or SERVICES, including economic damage or injury to property and lost profits, and including any damage arising from acts or negligence on the part of JACKSON, its agents or employees. Unless prohibited by law, in purchasing or receiving MICE, PRODUCTS, or SERVICES from JACKSON, purchaser or recipient, or any party claiming by or through them, expressly releases and discharges JACKSON from all such causes of action or damages, and further agrees to defend and indemnify JACKSON from any costs or damages arising out of any third party claims.

MICE, PRODUCTS or SERVICES are to be used in a safe manner and in accordance with all applicable governmental rules and regulations.

The foregoing represents the General Terms and Conditions applicable to JACKSON’s MICE, PRODUCTS or SERVICES. In addition, special terms and conditions of sale of certain MICE, PRODUCTS, or SERVICES may be set forth separately in JACKSON web pages, catalogs, price lists, contracts, and/or other documents, and these special terms and conditions shall also govern the sale of these MICE, PRODUCTS and SERVICES by JACKSON, and by its licensees and distributors.

Acceptance of delivery of MICE, PRODUCTS or SERVICES shall be deemed agreement to these terms and conditions. No purchase order or other document transmitted by purchaser or recipient that may modify the terms and conditions hereof, shall be in any way binding on JACKSON, and instead the terms and conditions set forth herein, including any special terms and conditions set forth separately, shall govern the sale of MICE, PRODUCTS or SERVICES by JACKSON.

Also Known As: motor neuron degeneration

Genetic overview

Research Applications

Base Price

Detailed Description

Control Suggestions

Additional Information

Selected References

Cln8mnd

Allele Symbol: Cln8mnd

Disease Terms

Model with phenotypic similarity to human disease where etiologies involve orthologs. Human genes are associated with this disease. Orthologs of those genes appear in the mouse genotype(s).

Research Areas By Genotype

This mouse can be used to support research in many areas including:

Genotype: Cln8mnd related

Mammalian Phenotype Terms by Genotype

Genotype: Cln8mnd/Cln8mndinvolves: AKR/J * B6.KB2

mortality/aging

vision/eye phenotype

nervous system phenotype

pigmentation phenotype

Genotype: Cln8mnd/Cln8mndinvolves: B6.KB2 * C3H/HeJ

mortality/aging

nervous system phenotype

Genotype: Cln8mnd/Cln8mndAK.B6(Cg)-Cln8

mortality/aging

nervous system phenotype

Genotype: Cln8mnd/Cln8mndB6.KB2/Rn-Cln8

behavior/neurological phenotype

nervous system phenotype

reproductive system phenotype

vision/eye phenotype

mortality/aging

Genotype: Cln8mnd/Cln8+involves: B6.KB2 * C57BL/6Fla

nervous system phenotype

Genotype: Cln8mnd/Cln8mndinvolves: B6.KB2

behavior/neurological phenotype

nervous system phenotype

References

Additional References

Additional - Cln8mnd related

Genotyping Protocols

Appearance

Citation

Animal Health Reports

Production of mice from cryopreserved embryos or sperm occurs in a maximum barrier room, G200

Live Mouse

Cryorecovery - Pricing

Payment Terms and Conditions

The Jackson Laboratory's Genotype Promise

Terms of Use

Licensing Information

JAX® Mice, Products & Services Conditions of Use

No Warranty

Credit for PRODUCTS or SERVICES

Animal Care and Use for SERVICES

No Liability

Cln8^mnd

Allele Symbol: Cln8^mnd

Genotype: Cln8^mnd related

Genotype: Cln8^mnd/Cln8^mnd
involves: AKR/J * B6.KB2

Genotype: Cln8^mnd/Cln8^mnd
involves: B6.KB2 * C3H/HeJ

Genotype: Cln8^mnd/Cln8^mnd
AK.B6(Cg)-Cln8

Genotype: Cln8^mnd/Cln8^mnd
B6.KB2/Rn-Cln8

Genotype: Cln8^mnd/Cln8⁺
involves: B6.KB2 * C57BL/6Fla

Genotype: Cln8^mnd/Cln8^mnd
involves: B6.KB2

Additional - Cln8^mnd related